OWP
CRSP icon

ORG Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

ORG Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818 Hold
15
– – ﹤0.01% 656
2026
Q1 		$713 Hold
15
– – ﹤0.01% 621
2025
Q4 		$786 Hold
15
– – ﹤0.01% 576
2025
Q3 		$972 Hold
15
– – ﹤0.01% 580
2025
Q2 		$727 Hold
15
– – ﹤0.01% 627
2025
Q1 		$497 Buy
+15
New +$636 ﹤0.01% 721

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ORG Wealth Partners's CRSP Position: Q2 2026 in Review

ORG Wealth Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 15 shares worth $818. The position accounts for ﹤0.01% of the portfolio, ranked #656.

ORG Wealth Partners first reported a position in CRSP in Q1 2025 and has held it in 6 quarters since. The position peaked at $972 in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • ORG Wealth Partners held 15 shares of CRISPR Therapeutics worth $818 as of Q2 2026.
  • ORG Wealth Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of ORG Wealth Partners's portfolio in Q2 2026, its #656 holding.
  • ORG Wealth Partners first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • ORG Wealth Partners's CRISPR Therapeutics position peaked at $972 in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on ORG Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.